Skip to main content
. 2012 Nov 28;54(1):1–14. doi: 10.3349/ymj.2013.54.1.1

Table 8.

No Difference in OS and RR between CT+Cetuximab vs. CT Alone in Asian Subgroup

graphic file with name ymj-54-1-i008.jpg

EGFR-TKIs, epidermal growth factor receptor tyrosine-kinase inhibitors; OS, overall survival; RR, response rate.

Small sample size (n=121, 10% of total) and difference in histology and post-study EGFR-TKI treatment do not allow to draw definitive conclusions.